Photo by nci from unsplash
e21184Background: Chemotherapy combined with antiangiogenic agents such as bevacizumab and ramucirumab has been shown to bring overall survival benefit for advanced NSCLC patients (pts). Apatinib i... Click to show full abstract
e21184Background: Chemotherapy combined with antiangiogenic agents such as bevacizumab and ramucirumab has been shown to bring overall survival benefit for advanced NSCLC patients (pts). Apatinib i...
Keywords:
apatinib combined;
combined docetaxel;
docetaxel egfr;
study apatinib;
egfr negative;
phase study
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!